Roche ends two Huntington’s disease drug programs after mixed HD2 results

Roche is discontinuing two Huntington’s disease drug programs: tominersen in the GENERATION HD2 trial, which lowered huntingtin and improved biomarkers but did not slow disease progression, and RG6496 in POINT-HD, halted after early data and long-term animal studies suggested dosing would be unsuitable. The decisions were not safety-related, and Roche will share more data later while continuing its unrelated RG6662 gene therapy program. The news underscores that huntingtin lowering remains a valid strategy but may require different approaches, dosing, or timing; participants’ contributions are acknowledged as the field moves forward.